Miltenyi Biotec

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024
Neuroscience, Toxicity, Doctor of Philosophy, FCCP, Lactation, FCP, Spectrum, Fear, Labroots, Associate, Anxiety, Networking hardware, Oxytocin, G protein-coupled receptor, Tumor microenvironment, QIAGEN, Drug discovery, Therapy, Digital image, DSM-IV codes, Thermo Fisher Scientific, Advantage Business Media, Laboratory, Miltenyi Biotec, Doctor of Pharmacy, MPS, Safety, Biomarker, Beta-lactam, Sartorius, Regulation, Master of Science, Merck, Epithelial–mesenchymal transition, Dean (education), Lung cancer, Cancer, Pharmaceutical industry

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®

Retrieved on: 
Monday, December 18, 2023
Biology, Phase, NY-ESO-1, Biomedical Research, Immunotherapy, Entrepreneurship, PRAME, IND, TCR, Antigen, Synovial sarcoma, DNA, Cancer, Monroe Dunaway Anderson, GMP, University, Miltenyi Biotec, Writing, Genome, Patient, Safety, Bone marrow, NK, Vaccine

Under the terms of the agreement, Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and The University of Texas MD Anderson Cancer Center in February 2023, has secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR.

Key Points: 
  • Under the terms of the agreement, Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and The University of Texas MD Anderson Cancer Center in February 2023, has secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR.
  • Miltenyi Biotec will use its CliniMACS Prodigy® closed and automated cell processing platform to manufacture a scalable, GMP-compliant, PRAME-targeted, TCR-NK cell therapy product for clinical development and provision of future commercial supply.
  • The Company’s first target, NY-ESO-1, is being investigated in relapsed or refractory multiple myeloma, synovial sarcoma, and myxoid/round cell liposarcoma.
  • In line with our mission to advance cell therapies to treat patients with cancer and other serious diseases, we’re excited to collaborate with Replay and the Syena team on their GMP-compliant PRAME TCR-NK cell therapy product.”

EQS-News: Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost! competition

Retrieved on: 
Wednesday, September 27, 2023
Huntington's disease, CRISPR, Neuron, Wuhan Institute of Biological Products, Therapy, Cell death, Genomics, Cancer, Research, Biomarker, RNA, Consultant, Qiagen, Plant, Botany, Heinrich Heine University Düsseldorf, Engineering, Rida al-Tubuly, Miltenyi Biotec, Synthetic biology, DSM-IV codes, Autoimmunity, Fine chemical, Pharmaceutical industry, Bookbinding, Plantman, Biotechnology, Bayer, Cologne

Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!

Key Points: 
  • Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!
  • Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!
  • competition
    Düsseldorf/Hilden, September 27, 2023: The winners of the 10th BioRiver Boost!
  • The Company develops novel CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools.

ATLATL Beijing International Innovation Center Becomes Fully Operational

Retrieved on: 
Tuesday, September 5, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Acceleration, GMP, Drug development, Center for Cell and Gene Therapy, CGT, Charles River Laboratories, Gene, Bio 360 Life Sciences Park, Seed, Danaher, Zhongguancun, Government, Boehringer Ingelheim, Plant, Laboratory, Novo Nordisk, Miltenyi Biotec, Cell, Ecosystem, PCR, Creative industries, Pharmaceutical industry, Fine chemical

Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.

Key Points: 
  • Phase II of the ATLATL Beijing International Innovation Center (referred to as "Beijing ATLATL"), located in the Zhongguancun Life Science Park, has officially commenced operations, marking the comprehensive launch of Beijing ATLATL.
  • Beijing ATLATL, initiated in 2021, has served more than 20 innovation teams, with total funding raised of more than 2 billion RMB.
  • Dr. PC Zhu, founder and CEO of ATLATL Innovation Center, stated that after more than two years in Beijing, ATLATL, leveraging its core R&D strength, has been vigorously constructing the Beijing ATLATL International Innovation Platform, pooling innovation and sourcing innovation.
  • Through sourcing and pooling innovation, ATLATL quickly connects China's biopharmaceutical innovation "seeds" with international resources, accelerates the development of "Life Valley" in Beijing, creates a globally leading innovation platform, and builds a world-class biopharmaceutical innovation cluster.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
BioLegend, PlayStation Portable system software, Disease, Drug development, Drug discovery, Cancer research, Sartorius AG, Personalized medicine, Functional analysis, Research, Medicine, Agilent Technologies, Cell, Automation, Miniaturization, Disulfiram-like drug, Danaher Corporation, Transplant, Neuroscience, Acquisition, Laboratory, Machine learning, Microbiology, Flow cytometry, Apoptosis, Cell cycle, Hematology, Miltenyi Biotec, Luminex Corporation, SPS, Robotics, AI, B cell, Sony, Behavior, Sysmex Corporation, Computer data storage, Mobile phone, Pharmaceutical industry, Medical imaging

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
BioLegend, PlayStation Portable system software, Disease, Drug development, Drug discovery, Cancer research, Sartorius AG, Personalized medicine, Functional analysis, Research, Medicine, Agilent Technologies, Cell, Automation, Miniaturization, Disulfiram-like drug, Danaher Corporation, Transplant, Neuroscience, Acquisition, Laboratory, Machine learning, Microbiology, Flow cytometry, Apoptosis, Cell cycle, Hematology, Miltenyi Biotec, Luminex Corporation, SPS, Robotics, AI, B cell, Sony, Behavior, Sysmex Corporation, Computer data storage, Mobile phone, Pharmaceutical industry, Medical imaging

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Global Cell Dissociation Market Analysis 2023-2028: Non-Enzymatic Tissue Dissociation - A Lucrative Market Opportunity - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Health, Other Health, GMP, Tissue, Connective tissue, Corning Inc., Therapy, Stemcell Technologies, Trypsin, Enzyme, ATCC, Merck Group, Research, Danaher Corporation, Certification, Becton, Dickinson and Company headquarters, Incidence, Investment, Growth, Miltenyi Biotec, Region, DNASE1L1, Fine chemical, Pharma, Papain

This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.

Key Points: 
  • This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.
  • The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total cell dissociation market.
  • Based on product, the cell dissociation market is segmented into enzymatic dissociation agents, non-enzymatic dissociation agents, and instruments & accessories.
  • Based on tissue type, the cell dissociation market has been segmented into connective tissue, epithelial tissue, and other tissues (muscle tissue, lung tissue, and nerve tissue).

EQS-News: Golding Capital Partners GmbH: Golding appoints Barbara Phélippeau as its first Partner for People & Culture

Retrieved on: 
Monday, July 3, 2023
HR, Philip Morris International, Miltenyi Biotec, Empathy, Knauf Insulation, Culture, Management, Golding

“Barbara Phélippeau brings some 25 years of experience, and an enormous breadth and depth of HR expertise.

Key Points: 
  • “Barbara Phélippeau brings some 25 years of experience, and an enormous breadth and depth of HR expertise.
  • This experience, the values she personifies every day, and her innovative concepts make her an ideal fit for us.
  • So I am delighted that we have been able to enlist Barbara specifically to develop these areas”, says Jeremy Golding, Founder and Managing Partner of Golding.
  • Barbara Phélippeau is a fully qualified lawyer, who studied in Mannheim, specialising in business and company law.

BIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Retrieved on: 
Thursday, June 1, 2023
Probability, VL, VH, Marketing, Complementarity, Antibody, Bio-Techne, Animal, TIGIT, Higher Regional Court of Cologne, Sąd rejonowy, Court, R, Fine chemical, Miltenyi Biotec

MINNEAPOLIS, June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.

Key Points: 
  • MINNEAPOLIS, June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.
  • Specifically, the Court held "it has been proven that [Miltenyi's] TIGIT and CCR-7 antibodies are the result of reverse engineering of [Bio-Techne's] antibodies."
  • In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodies, the court determined that Bio-Techne is entitled to monetary damages and additional detailed information regarding the scope of Miltenyi's unlawful reverse engineering activities.
  • This discovery took place following suspicious purchasing activity from Miltenyi for these specific R&D Systems branded antibodies spanning more than a decade.

Vector BioMed Appoints Jakob Reiser, Ph.D., as Senior Director of Regulatory Affairs

Retrieved on: 
Tuesday, April 11, 2023
Vector, GMP, Doctor of Philosophy, CBER, Center for Biologics Evaluation and Research, Gene, Louisiana State University Agricultural Center, MBA, Associate, Bangladesh Technical Education Board, CAR, LSU, Investigational New Drug, University of Texas Health Science Center at San Antonio, Regulatory affairs, Miltenyi Biotec, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, BLA, NIH, Food, Safety, Vaccine, Research

GAITHERSBURG, Md., April 11, 2023 /PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced the appointment of Jakob Reiser, Ph.D., to the position of Senior Director, Regulatory Affairs, as the Company expands its team to offer a best-in-class lentiviral vector platform to aid in the development of innovative gene therapies.  Dr. Reiser brings more than 45 years of scientific and regulatory experience to Vector BioMed including nearly 15 years as a principal investigator at the Center for Biologics Evaluation and Research (CBER), part of the U.S. Food and Drug Administration (FDA).

Key Points: 
  • "Dr. Reiser is a key addition to Vector BioMed's senior leadership team, bringing to the company a world-renowned scientist and leading expert in the field of lentiviral vector research and development," said Boro Dropulić, Ph.D., MBA, CEO of Vector Biomed.
  • As Senior Director of Regulatory Affairs at Vector BioMed, Dr. Reiser will apply his expertise to support partners in their regulatory strategy and submissions in order to advance their clinical-stage programs."
  • Prior to joining Vector BioMed, Dr. Reiser spent nearly 15 years as a principal investigator at CBER where he led a laboratory focused on the safety and manufacture of lentiviral vectors.
  • We have developed an efficient lentiviral vector manufacturing process that yields very high vector titer and quality.